These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 20470383)

  • 21. High-density lipoprotein composition and paraoxonase activity in Type I diabetes.
    Valabhji J; McColl AJ; Schachter M; Dhanjil S; Richmond W; Elkeles RS
    Clin Sci (Lond); 2001 Dec; 101(6):659-70. PubMed ID: 11724654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux.
    Rosenblat M; Gaidukov L; Khersonsky O; Vaya J; Oren R; Tawfik DS; Aviram M
    J Biol Chem; 2006 Mar; 281(11):7657-65. PubMed ID: 16407304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of HDL mimetic peptide 4F on PON1.
    Vakili L; Hama S; Kim JB; Tien D; Safarpoor S; Ly N; Vakili G; Hough G; Navab M
    Adv Exp Med Biol; 2010; 660():167-72. PubMed ID: 20221879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measurement of serum paraoxonase-1 activity in the evaluation of liver function.
    Camps J; Marsillach J; Joven J
    World J Gastroenterol; 2009 Apr; 15(16):1929-33. PubMed ID: 19399923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iron-ascorbic acid-induced oxidant stress and its quenching by paraoxonase 1 in HDL and the liver: comparison between humans and rats.
    Trudel K; Sinnett D; James RW; Delvin E; Amre D; Seidman E; Levy E
    J Cell Biochem; 2005 Oct; 96(2):404-11. PubMed ID: 16052486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for the presence of active paraoxonase 1 in small-dense low-density lipoprotein.
    Gugliucci A; Caccavello R; Kotani K; Kimura S
    Redox Rep; 2014 Jul; 19(4):154-60. PubMed ID: 24524596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overweight and obesity in polycystic ovary syndrome: association with inflammation, oxidative stress and dyslipidaemia.
    Perovic Blagojevic IM; Vekic JZ; Macut DP; Ignjatovic SD; Miljkovic-Trailovic MM; Zeljkovic AR; Spasojevic-Kalimanovska VV; Bozic-Antic IB; Bjekic-Macut JD; Kastratovic-Kotlica BA; Andric ZG; Ilic DS; Kotur-Stevuljevic JM
    Br J Nutr; 2022 Aug; 128(4):604-612. PubMed ID: 34511137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The paraoxonase 1, 2 and 3 in humans.
    Rajkovic MG; Rumora L; Barisic K
    Biochem Med (Zagreb); 2011; 21(2):122-30. PubMed ID: 22135851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis.
    Asefi M; Vaisi-Raygani A; Bahrehmand F; Kiani A; Rahimi Z; Nomani H; Ebrahimi A; Tavilani H; Pourmotabbed T
    Br J Dermatol; 2012 Dec; 167(6):1279-86. PubMed ID: 22835076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity.
    James RW; Deakin SP
    Free Radic Biol Med; 2004 Dec; 37(12):1986-94. PubMed ID: 15544917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extra-virgin olive oil consumption reduces the age-related decrease in HDL and paraoxonase 1 anti-inflammatory activities.
    Loued S; Berrougui H; Componova P; Ikhlef S; Helal O; Khalil A
    Br J Nutr; 2013 Oct; 110(7):1272-84. PubMed ID: 23510814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ApoE induces serum paraoxonase PON1 activity and stability similar to ApoA-I.
    Gaidukov L; Viji RI; Yacobson S; Rosenblat M; Aviram M; Tawfik DS
    Biochemistry; 2010 Jan; 49(3):532-8. PubMed ID: 20025294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of dietary lipids on paraoxonase-1 activity and gene expression.
    Ferretti G; Bacchetti T
    Nutr Metab Cardiovasc Dis; 2012 Feb; 22(2):88-94. PubMed ID: 22118836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum paraoxonase 1 activity is associated with fatty acid composition of high density lipoprotein.
    Boshtam M; Razavi AE; Pourfarzam M; Ani M; Naderi GA; Basati G; Mansourian M; Dinani NJ; Asgary S; Abdi S
    Dis Markers; 2013; 35(4):273-80. PubMed ID: 24167374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles.
    Marathe GK; Zimmerman GA; McIntyre TM
    J Biol Chem; 2003 Feb; 278(6):3937-47. PubMed ID: 12466264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of homocysteinylation on high density lipoprotein physico-chemical properties.
    Ferretti G; Bacchetti T; Masciangelo S; Bicchiega V
    Chem Phys Lipids; 2010 Feb; 163(2):228-35. PubMed ID: 19962972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. VLDL triglycerides inhibit HDL-associated paraoxonase 1 (PON1) activity: in vitro and in vivo studies.
    Rosenblat M; Ward S; Volkova N; Hayek T; Aviram M
    Biofactors; 2012; 38(4):292-9. PubMed ID: 22674772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human carotid plaque phosphatidylcholine specifically interacts with paraoxonase 1, increases its activity, and enhances its uptake by macrophage at the expense of its binding to HDL.
    Cohen E; Aviram M; Khatib S; Artoul F; Rabin A; Mannheim D; Karmeli R; Salamon T; Vaya J
    Free Radic Biol Med; 2014 Nov; 76():14-24. PubMed ID: 25091896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alteration of HDL functionality and PON1 activities in acute coronary syndrome patients.
    Bounafaa A; Berrougui H; Ikhlef S; Essamadi A; Nasser B; Bennis A; Yamoul N; Ghalim N; Khalil A
    Clin Biochem; 2014 Dec; 47(18):318-25. PubMed ID: 25218815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The contribution of high density lipoprotein apolipoproteins and derivatives to serum paraoxonase-1 activity and function.
    James RW; Deakin SP
    Adv Exp Med Biol; 2010; 660():173-81. PubMed ID: 20221880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.